Merck To Focus Taranabant Development On Lower Dose
This article was originally published in The Pink Sheet Daily
Executive Summary
Cannabinoid-1 receptor blocker shows weight loss benefits with lower adverse psychiatric events at 2 mg dose in Phase III.